Opendata, web and dolomites

ExtremoChem

Chemically synthesised novel compounds for the stabilisation of biologics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ExtremoChem project word cloud

Explore the words cloud of the ExtremoChem project. It provides you a very rough idea of what is the project "ExtremoChem" about.

lower    source    commercial    humira    medical    arthritis    small    molecules    20    sign    restored    potency    quality    once    insulins    degrade    line    trial    chain    blood    interferins    lost    organic    obtain    aggregation    native    otherwise    market    size    biotechnology    validation    salinity    biologics    suitable    savings    ph    vaccines    compounds    mabs       rheumatoid    white    medicines    strict    synthetic    tests    purification    direct    biological    stabilization    protects    wasted    agitation    biopharmaceutical    business    safety    12    least    degradation    drugs    neupogen    consisting    biopharmaceuticals    cold    stages    biologic    preserve    carbons    issue    reachable    full    prepare    stabilise    material    revenues    synthesises    assuring    cells    effectiveness    elaborate    thermally    industrial    share    stressful    stability    extraction    extremochem    sound    volume    preventing    plan    storage    clinical    feasible    temperatures    subject    sensitive    critical    proteins   

Project "ExtremoChem" data sheet

The following table provides information about the project.

Coordinator
EXTREMOCHEM LDA 

Organization address
address: Estrada Municipal 528, 1
city: IGREJINHA
postcode: 7040-220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://extremochem.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXTREMOCHEM LDA PT (IGREJINHA) coordinator 50˙000.00

Map

 Project objective

Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety. Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency. Once potency is lost, it cannot be restored, this means the biologic is wasted.

ExtremoChem synthesises a line of novel compounds consisting of synthetic small organic molecules, from 8 to 12 carbons, that are able to stabilise proteins and other biological material by preventing their degradation under stressful conditions, such as higher or lower temperatures, pH, salinity, agitation under which they would otherwise degrade. eXtremochem is suitable for a wide range of proteins such as mAbs, vaccines, insulins, interferins and etc. But ExtremoChem currently focuses on mAbs, such as Humira (for rheumatoid arthritis) & Neupogen (for growth of white blood cells), since they present a high value market. The eXtremochem compounds improve the stability of molecules in the most critical purification stages and protects biologics, preventing aggregation and increasing production volume by 20%. Furthermore, eXtremochem enables long-term storage of thermally sensitive biologics without the need for cold chain, thus bringing significant savings to biopharmaceuticals – 6.5% of their revenues.

The Phase 1 project will allow ExtremoChem to evaluate the medicines’ degradation under the presence of the small organic molecules through several stabilization tests, prepare a feasible industrial scale-up plan, plan a sound Ph 1 clinical trial, elaborate the business scale up, and size the reachable market and a reliable market share. Within the overall project, ExtremoChem aims to: obtain the clinical validation and sign at least one commercial agreement.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXTREMOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXTREMOCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More